|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table S1. Donor and Recipients** **characteristics, stratified by donor type and recipient status** | | | | | | | | |
| Characteristics | | SCD+IGF(n=349) | | | SCD+DGF(n=72) | ECD+IGF(n=85) | ECD+DGF(n=35) | *P* | |
| Donor characteristic | |  | | |  |  |  |  |
| Age (years) | | 40[28,45] | | | 38[32.25,44] | 55[52,60] | 55[52,58] | <0.001 |
| Female sex | | 53(15) | | | 11(15) | 15(18) | 5(17) | 0.947 |
| BMI (kg/m2) | | 22.90[21.10,24.10]a | | | 22.90[21.50,24.50] | 23.40[22.00,24.50] | 22.50[20.80,23.70] | 0.15 |
| Cause of death | |  | | |  |  |  |  |
| Cerebrovascular accident | | 112(32) | | | 25(35) | 24(29) | 13(38) | 0.904 |
| Head trauma | | 209(60) | | | 39(54) | 53(62) | 19(56) |  |
| other | | 28(8) | | | 8(11) | 8(9) | 3(6) |  |
| Terminal serum creatinine (umol/l) | | 120[86,155] | | | 145.5[98,230] | 125[81,159] | 137[108,261] | 0.002 |
| Donor proteinuria level | |  | | |  |  |  | 0.180 |
| 0 | | 199(57) | | | 41(56) | 41(48) | 13(37) |  |
| 1+ | | 91(26) | | | 19(26) | 27(32) | 9(26) |  |
| 2+ | | 35(10) | | | 6(8) | 10(12) | 6(17) |  |
| 3+ | | 24(7) | | | 6(8) | 7(8) | 7(20) |  |
| Warm ischemia time (min) | |  | | |  |  |  | <0.001 |
| ≤18 min | | 275(79) | | | 43(60) | 56(66) | 9(26) |  |
| ＞18min | | 74(21) | | | 29(40) | 29(34) | 26(74) |  |
| Recipient characteristic | |  | | |  |  |  |  |
| Age | | 43[34,50] | | | 41[31.25,48.75] | 45[35.5,55.50] | 45[33,51] | 0.066 |
| Male sex | | 221(63) | | | 46(64) | 55(65) | 24(69) | 0.031 |
| BMI (kg/m2) | | 22.31[21.01,24.74]a | | | 22.40[21.42,24.62] | 22.21[21.28,24.51] | 22.56[21.62,24.95] | 0.526 |
| Cause of ESRD | |  | | |  |  |  | 0.998 |
| Hypertension | | 73(21) | | | 13(18) | 19(22) | 7(20) |  |
| Diabetes | | 87(25) | | | 19(27) | 17(20) | 8(24) |  |
| GN | | 122(35) | | | 23(32) | 30(36) | 12(34) |  |
| PKD | | 35(10) | | | 10(14) | 10(12) | 4(11) |  |
| Others | | 32(9) | | | 7(9) | 9(10) | 4(11) |  |
| Mode of dialysis | |  | | |  |  |  | 0.336 |
| HD | | 294(84) | | | 66(91) | 75(88) | 31(88) |  |
| PD | | 55(16) | | | 6(9)a | 10(12) | 4(12) |  |
| Dialysis duration, mo | | 12[7,24] | | | 12[8.25,24] | 12[9,24] | 13[8,25] | 0.597 |
| Cold ischemia time, h | | 5[2,6] | | | 4[2,5.75] | 5[2,6] | 5[2,7] | 0.278 |
| Number of HLA mismatches | |  | | |  |  |  | 0.898 |
| Level1 | | 269(77) | | | 58(80) | 70(82) | 27(76) |  |
| Level2 | | 42(12) | | | 9(12) | 9(11) | 4(12) |  |
| Level3 | | 38(11) | | | 5(8) | 6(7) | 4(12) |  |
| Panel active antibody | |  | | |  |  |  | 0.624 |
| Positive | | 35(10) | | | 6(9) | 11(13) | 2(7) |  |
| Negative | | 314(90) | | | 66(91) | 74(87) | 33(93) |  |
| Induction regimen | |  | | |  |  |  | 0.010 |
| ATG | | 283(81) | | | 48(67) | 70(82) | 23(65) |  |
| Basiliximab | | 66(19) | | | 24(33) | 15(18) | 12(35) |  |
| CNI | |  | | |  |  |  | 0.908 |
| Cyclosporin | | 105(30) | | | 23(32) | 24(28) | 9(27) |  |
| Tacrolimus | | 244(70) | | | 49(68) | 61(72) | 26(73) |  |
| Rejection | |  | | |  |  |  | 0.939 |
| Antibody mediated rejection | | | | 19(5) | 5(7) | 5(6) | 3(8) |  |
| T cell mediated rejection | | | 15(4) | | 6(8) | 4(5) | 3(8) |  |
| Infection | |  | | |  |  |  | 0.952 |
| Urinary tract infection  Pneumonia | | | | 22(6)  29(8) | 8(11)  14(19) | 6(7)  9(11) | 4(11)  5(14) |  |
| Proteinuria rate 5-year posttransplantation | | 31(9) | | | 9(12) | 12(14) | 11(30) | 0.001 |
| Renal functions 5-year Posttransplantation | 76[94,59] | | | | 74[84,56] | 68[76,57] | 57[74,46] | <0.001 |
| Continuous variables according to the Shapiro test, if P>0.05 the data are expressed as mean±SD, otherwise data are expressed as median [P25,P75]; Categorical variables are described by numbers and percentages (%).  Continuous variables were compared using ANOVA or Kruskal-Wallis tests, categorical variables were compared using the χ2 test and Fisher’s exact test.  Abbreviation: DGF: delayed graft function; BMI: body mass index; ESRD: end-stage renal disease; GN: glomerulonephritis; PKD: polycystic kidney disease; HD: hemodialysis; PD: peritoneal dialysis; HLA: human leukocyte antigen; CNI: calcineurin inhibitor; ATG:Antithymocyte globulin. | | | | | | | | |